Abbott Hopes To Prevent Heart Failure Hospitalizations With New CardioMEMS HF Labeling
The FDA expanded the indication for Abbott’s CardioMEMS HF wireless heart failure monitor to include patients who have never been hospitalized for heart failure before.
You may also be interested in...
Abbott executives Philip B. Adamson and Robert Kormos talked to Medtech Insight about how the company is trying to slow the progression of heart failure and reduce heart failure hospitalizations.
The GUIDE HF investigators contend the trial missed its primary endpoint because of COVID-19.
Paolo Di Vincenzo, the general manager of Smith+Nephew's US advanced wound management business will join Medtronic as the president of its neuromodulation business.